PDF icon PDF herunterladen
Semin Thromb Hemost 2018; 44(08): 813-822
DOI: 10.1055/s-0038-1673690
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation

Bassel Nazha
1   Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
,
Bhavi Pandya
2   Division of Cardiology, Staten Island University Hospital – Northwell Health, Staten Island, New York
,
Alex C. Spyropoulos
3   Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York
4   Department of Medicine, Hofstra Northwell School of Medicine, Hempstead, New York
5   Department of Medicine, Anticoagulation and Clinical Thrombosis Service, Northwell Health at Lenox Hill Hospital, New York, New York
,
Craig M. Kessler
6   Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia
› Institutsangaben
Funding Sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Oktober 2018 (online)

   Lizenzen und Reprints
Preview

Abstract

Venous thromboembolism (VTE) is a leading cause of morbidity with potentially detrimental career consequences in elite athletes. Their unique predisposing factors entail a higher-than-expected VTE incidence. Anticoagulation treatment is challenging, especially among those athletes wishing to resume their competitive activities. The authors review the current VTE treatment guidelines from the perspective of treating elite athletes. They then provide an expert opinion individualized treatment approach based on the pharmacokinetic properties of direct oral anticoagulants that permits tailoring the drug's timing to the athlete's competitive endeavors. They also present low-molecular-weight heparin as an alternative. The proposed risk management approach allows mitigation against VTE recurrence, reducing the chance of major bleeding, and honoring the athlete's self-determination to resume their career while accepting the risks involved. A shared decision making with the athlete and his/her team along with the presence of adequate resources are key components. Ultimately, the authors hope this work will serve as a stepping stone to validated VTE treatment regimens that consider the particularities of elite athletes.

Keywords

direct oral anticoagulants - athletes - venous thromboembolism - expert opinion - anticoagulation - deep vein thrombosis - pulmonary embolism